跳至主要内容
临床试验/NCT03568409
NCT03568409已完成不适用

Efficacy of ABO-GLYC on Glycemic and Metabolic Status of Patients With Type 2 Diabetes

Aboca Spa Societa' Agricola1 个研究点 分布在 1 个国家目标入组 86 人开始时间: 2017年6月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
86
试验地点
1
主要终点
Improvement of the overall glycemic control after 6 months of treatment with ABO-GLYC, as a result of reduction of HbA1c and/or post-prandial glycemic peak.

研究概览

简要总结

Evaluation of the improvement of the overall glycemic control after 6 months of treatment with ABO-GLYC, as a result of reduction of HbA1c and/or post-prandial glycemic peak.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female patients with diagnosis of type 2 diabetes, aged 18-75
  • HbA1c at screening between 6.5% and 7.5%
  • Last 2 HbA1c values in the last 12 months between 6.5% and 7.5%
  • Intolerance to metformin without unquestionable indication to other oral hypoglycemic agents
  • BMI 25-38 kg/m2
  • Willing and able to understand and sign the informed consent and complete the patient diary provided
  • Women participant of childbearing age should be negative to pregnancy test (performed on blood), and will have to use an appropriate contraceptive method throughout the study.

排除标准

  • Micro and macrovascular complication of diabetes in advanced stage (i.e., proliferative diabetic retinopathy; chronic renal failure III-IV stage KDOQI)
  • Chronic gastro-intestinal disease
  • Heavy smoker subjects
  • Alcohol abuse
  • Chronic liver and kidney disease (AST or ALT values > 2.5 UNL or plasma creatinine > 1.5 mg/dl)
  • Previous major gastrointestinal surgery
  • History of eating disorders
  • Pregnancy or lactation
  • Use of food supplements containing in particular but not limited to fibers and polysaccharides, in the last six months with frequency and dosage such as to interfere with the study.
  • Autoimmune diseases
  • Known hypersensitivity to any of the components of the product.
  • Any condition which prevent subject participation in the opinion of the principal investigator.

结局指标

主要结局

Improvement of the overall glycemic control after 6 months of treatment with ABO-GLYC, as a result of reduction of HbA1c and/or post-prandial glycemic peak.

时间窗: Week0 and Week24

HbA1c measure

次要结局

  • Improvement of markers of glycemic variability (HBGl)(Week0 to Week24)
  • Improvement of markers of glyco-oxidative stress(Week0 to Week24)
  • Improvement in markers of insulin secretion after standardized meal.(Week 0 and Week 24)
  • Improvement of markers of glycemic variability (MAGE)(Week0 to Week24)
  • Improvement of markers of glycemic variability (LBGI)(Week0 to Week24)
  • Improvement of markers of metabolic status (BMI)(Week0 to Week24)
  • Evaluation of gut microbiome changes (bacteria population)(Week 0, Week 1, Week 12, Week 24)
  • Improvement of markers of glycemic variability (plasma glucose level)(Week0 to Week24)
  • Improvement of markers of glycemic variability (hypo/hyper glycemia)(Week0 to Week24)
  • Improvement of markers of inflammation(Week0 to Week24)
  • Improvement of markers of metabolic status (lipid profile)(Week0 to Week24)
  • Improvement of markers of metabolic status (body composition)(Week0 to Week24)
  • Control of the glycemia.(Week0 to Week24)
  • Evaluation of gut microbiome changes (SCFA)(Week 0, Week 1, Week 12, Week 24)
  • Improvement in markers of insulin resistance(Week 0 and Week 24)
  • Evaluation of the dietary adherence(Week0 to Week24)
  • Adverse events (AEs) evaluation and product tolerability.(Week0 to Week24)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

ABO-GLYC in Type 2 Diabetes | 临床试验